ArticleScientific reports2026
The effect of preemptive use of nonsteroidal anti-inflammatory drug on inflammation, oxidative stress, and wound healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of preemptively administered nonsteroidal anti-inflammatory drugs (NSAIDs) on wound healing, inflammation, and oxidative stress in rats. 24 male Sprague-Dawley rats were assigned to four groups: no NSAID (Control), preemptive NSAID (Group 1), postoperative NSAID (Group 2), and pre- and postoperative NSAID (Group 3). As a NSAID, Celecoxib (20 mg/kg/day) was administered via oral gavage. A standardized mandibular burr-hole bone defect was created. Animals were euthanized at 1, 2, or 4 weeks postoperatively. Bone healing was evaluated histologically using the Emery scoring system. M1 and M2 macrophages were identified via immunohistochemistry. Interleukin-1β, interleukin-6, interleukin-10, transforming growth factor-β, prostaglandin E₂, and oxidative stress markers including total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI) were measured using enzyme-linked immunosorbent assay. No statistically significant differences were observed among groups in bone healing scores, macrophage counts, or cytokine levels; however, TAS was significantly higher in Group 1 and lower in Group 2 at week 1 (p = 0.023). OSI showed a consistent temporal pattern, with Group 1 exhibiting the lowest OSI at week 1, although this difference was not statistically significant. Given the small sample size, these findings should be interpreted as preliminary and hypothesis-generating rather than conclusive. Preemptive celecoxib administration appeared to modulate early inflammatory and oxidative responses without impairing bone regeneration. Further adequately powered studies are required to confirm these early trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.